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Abstract: The achievements in multiple sclerosis (MS) therapeutics are founded on the
outcomes of clinical trials that demonstrate quantifiable results in treating a disease with
an unpredictable course. Much has changed since the early trials in MS from the mid-20th
century that compared a potential therapeutic agent with a placebo and measured outcomes
based on patients’ subjective reports. Advancements over the past decades have simplified
diagnosis of the disease and allowed for more quantitative monitoring of its progression
alongside support from paraclinical studies. Further collaborative efforts have led to pivotal
meetings that steered the direction of future trials and the creation of patient databases
that provided important epidemiologic information on trial subjects. These innovations and
changes have improved MS clinical trials but challenge future trials to create more efficient
designs lest the pace of progress necessarily slows because of the increased time to conduct
such studies. As treatment options for MS broaden, clinical trials will continue to incorporate
new strategies to identify novel therapies and pathways of intervention.
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Introduction
Clinical trials in multiple sclerosis (MS) have led
to the introduction of 15 therapeutic agents in the
span of just over two decades. Prior to the modern era of these MS therapies, initial treatments of
the disease during the early 20th century were
empirical or experience driven and studies on
potential agents were scarce and unregulated.
Investigators noted many difficulties in conducting clinical trials in MS. The incomplete understanding of the disease process hindered
development of therapies, and the sporadic course
of MS coupled with the lack of biomarkers created difficulties in monitoring disease progression. In order to detect differences in treatments,
large patient populations must be followed for
long durations due to the slow evolution of clinical changes. Trials are often seen as more efficient
when the population is more homogeneous.
Thus, the heterogeneity of the disease excluded
many patients with MS from trials due to narrow
inclusion criteria. Despite these challenges, the
significant achievements in MS therapies today
relied directly on clinical trials that proved their
journals.sagepub.com/home/tan

efficacy. This article reviews key events and developments that shaped the landscape of MS clinical
trials.
Early studies
The first clinical trials in MS took place in the
second half of the 20th century. Early trials were
limited in their design due to lack of established
criteria for diagnosing MS and objective measurements of disease progression. In 1961, Miller and
colleagues published the results of the first double-blind clinical trial in MS studying the effects
of adrenocorticotropic hormone (ACTH) on
neurological recovery during acute MS exacerbations.1 The study enrolled 40 “consecutive
patients with unequivocal MS, who presented
with an assessable new symptom or sign of less
than 14 days’ duration and showing no spontaneous improvement”. Subjects were matched in
sex, age, disease duration, and number of exacerbations, and randomized to receive either ACTH
or saline injections for their MS attacks. The
authors stated that “the groups were generally
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comparable in sex-distribution, age, and duration
of the disease, as well as in the proportions classified as showing initial episodes of multiple sclerosis, second or subsequent attacks during
remission, or acute exacerbations of an existing
disability of less than 10 years’ standing”.
However, if one were to look critically, it is likely
that the two groups were poorly matched, as it
was difficult to do this sequentially with a small
sample size. Results showed that ACTH improved
symptoms during an exacerbation, but this was
measured entirely through subjective reports
from patients in a follow-up interview.
At the time, the absence of established and objective outcome measurements along with the uncertainty of characterizing relapses hindered studies
from producing reliable data. The sporadic nature
of the disease challenged investigators to not only
find promising treatments but to devise ways to
assess their efficacy. In 1969, Rose and colleagues
conducted the first multicenter MS trial across 10
academic institutions in the USA.2,3 This was
another well-controlled, randomized doubleblind trial to study ACTH in the treatment of MS
attacks. More importantly, the study aimed to
determine whether a therapeutic agent can be
reliably assessed. The investigators employed various quantitative methods to assess neurologic
functions, among which was the disability status
scale (DSS), that would be revised later to become
the golden standard of outcome measures in MS
trials.4 The study concluded that therapeutic
agents can be objectively studied in patients with
MS. Although results suggested only modest
effects of ACTH in the setting of MS exacerbation, ACTH was widely employed for the treatment of MS for the next 15 years, eventually
leading to high-dose intravenous methylprednisolone as a treatment for MS exacerbations.
Advancement of imaging techniques
Another major evolution over time is the growth
and importance of magnetic resonance imaging
(MRI) in the diagnosis of MS and monitoring of
disease activity. This technology now has widespread use in clinical trials and has been central in
proof-of-concept studies. Prior to the development of MRI, computerized tomography (CT)
scans were unable to identify most MS lesions,
and many patients with MS had normal CT
scans. When contrast CT scans were first introduced to study MS lesions in 1976, enhancing
2

lesions could be seen and became associated with
so-called active disease.5 These lesions also
appeared to clear with steroid use.6 When MRI
was initially utilized in studies of MS in 1981,
researchers immediately noticed striking differences between MRI and CT regarding the appearance of lesions. In one of the early studies
comparing the two imaging modalities among 10
patients with definite and possible MS, CT captured 19 lesions whereas MRI captured 131
lesions.7 MRI showed continuous activity of new
lesions even in the absence of clinical symptoms,
suggesting its usefulness in monitoring subclinical
disease progression.8 In addition, imaging outcomes are more sensitive to change than clinical
measures, thus requiring smaller sample size and
study duration to detect treatment differences.
This is especially valuable for early proof-of-concept trials but may be tied to the main focus of
clinical interventions thus far in MS of reducing
inflammation and the attendant consequences.
The utility of other pathways of damage such as
neuroprotection and/or neurorepair has yet to be
shown.
In the 1990s MRI became a popular tool for providing secondary and even primary outcome
measures in drug studies. In the 5-year, 1988–
1993, placebo-controlled trial of interferon-beta1b that showed a significant reduction in the
frequency of MS attacks in the treatment group,
MRI was used as an outcome measure and
showed 80% fewer active scans and new lesion
developments compared with placebo.9 The evidence was perhaps even more compelling biologically than the clinical data in the US Food and
Drug Administration’s (FDA) approval of the
drug in 1993. As MRI became more widely used
in clinical trials, researchers gained a better
understanding of its utilities and limitations.
Many MS trials have used MRI to measure disease burden and monitor disease activity.10 The
use of gadolinium contrast showing enhancement
of lesions indicating active blood-brain-barrier
breakdown has been an important tool in confirming active MS lesions.11 In addition to measuring lesions, MRI has also been used to assess
unfractionated or fractionated atrophy, which
corresponds to some clinical disease markers.12
Despite these utilities, MRI lesions found on a
single or annual basis have not consistently been
shown to correlate with individual clinical outcomes in trials.13 However, Sormani and colleagues have shown that at the group level such
journals.sagepub.com/home/tan
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correlations do exist.14 Despite the radiologic utility of MRI, there is a need for improved MRI and
clinical methods to characterize accurately disease states and quantify progression.

categories of definite and probable MS.20 This
became widely accepted as the diagnosis of MS
and altered the enrollment criteria of clinical trials
to accept only clinically definite and probable
cases of MS.

Evolution of diagnostic criteria for MS
The diagnosis of MS and classification of its disease course have important implications for clinical trial design and outcomes. MS presents with
varying clinical signs and symptoms and follows
unpredictable disease courses, making it difficult
for trials to acquire homogeneous populations to
be able to determine differences in treatment
effects. Finding these so-called homogeneous
groups has been a challenge. Since the first formal diagnostic criteria of MS in 1965 that introduced the principles of dissemination in space
(DIS) and time (DIT),15 progress in our understanding of the disease and tools to study its
clinical course have led to more accurate and
simplified criteria.

The widespread use of MRI in the evaluation of
MS led to the development of the McDonald criteria in 2001, which introduced MRI results as
surrogates for the criteria of DIS and DIT.21 This
resulted in earlier and more sensitive diagnosis.22
With its revisions in 200523 and 2010,24 the criteria has been further simplified in which a single
MRI study could fulfill the requirements of DIS
and DIT. The most recent modifications in 2017
continue to facilitate the diagnosis by introducing
changes where the presence of oligoclonal bands
can fulfill the criteria of DIT.25 In addition,
requirements for DIS and DIT were further
broadened to include cortical lesions and symptomatic lesions excluding the optic nerve on MRI.

Early attempts to diagnose and categorize MS
focused on identifying clinical patterns of symptoms as exemplified by Charcot’s triad of nystagmus, intention tremor, and scanning
speech.16 Other classifications sorted patients
into categories corresponding to disease course
as defined by progression and relapses.17,18
There was a lack of unified guidelines, and diagnoses relied heavily on the clinician’s intuition
rather than objective guidelines. The first incorporation of the modern-day diagnostic requirement of DIS and DIT was presented in the
Schumacher criteria in 1965 as a result of a
committee headed by George Schumacher to
develop criteria for classifying MS.15 DIS was
defined as objective abnormalities in at least two
central nervous system white matter locations,
while DIT described their occurrence in two or
more episodes lasting more than 24 hours and
separated by at least 1 month or progressing
over 6 months. The Schumacher criteria simplified MS trial design and allowed for objective
diagnosis of clinically definite MS.15
With the development of laboratory and imaging
studies to diagnose MS, Poser published criteria
in 1983 that incorporated paraclinical studies
such as imaging and cerebrospinal fluid (CSF)
studies in the diagnosis of MS.19 The Poser criteria elaborated on the clinical classifications of the
Schumacher criteria and grouped patients into
journals.sagepub.com/home/tan

The evolution of MS diagnostic criteria had significant implications for clinical trials. As diagnostic criteria became more sensitive, more
patients were diagnosed earlier in the disease
course. In a population of 309 patients who presented with clinically isolated syndrome (CIS)
who were evaluated a year later, 16% of the
cohort were diagnosed with MS under the Poser
criteria compared to 44% using the McDonald
criteria, suggesting patients were diagnosed earlier in their disease course under more recent criteria.26 Another study showed that 50% of
patients with CIS under the 2001 McDonald criteria would be diagnosed with definite MS within
a year, while only 20% would under the Poser criteria. The apparently improved prognosis of CIS
and MS groups is a result of the changing diagnostic criteria shifting classification of patients
from higher risk groups into lower risk groups, an
effect known as the Will Rogers phenomenon
and/or lead time bias.27 This limits comparison of
historical MS populations with modern groups.
Further, another concern is that when sensitivity
is increased the risk of false positives (i.e. lowered
specificity) can often occur. This has only been
conjectured, and not formally validated.
Defining outcome measurements
In order to determine the efficacy of a potential
therapeutic agent for MS, investigators were
challenged with devising meaningful outcome
3
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measurements of clinical activity. The complex
clinical course of MS and the lack of biomarkers
impeded the development of an objective scale to
measure and track clinical changes. Prior to 1950,
evaluations of therapeutic efficacy were conveyed
by patients’ subjective reports on whether symptoms were better, worse, or unchanged, similar in
concept to modern-day patient-reported outcomes. The first attempts to develop objective
scales were made by Arkin and colleagues in 1950
and Alexander in 1951.28,29 Alexander’s approach
consisted of complex scales scoring 30 neurologic
signs, and proved to be cumbersome and lacked
refinement. In 1955 Kurtzke developed a scale
that could characterize the disability of a patient
with MS and reflect changes in clinical status
while maintaining simplicity.4 The patient was
assigned a degree of disability from 0 (normal
neurologic exam) to 10 (death due to MS). The
DSS was first used in a study of isoniazid as therapy for MS, which was also the first multicenter,
randomized, placebo-controlled, double-blind
trial of a disease-modifying therapy (DMT) in
patients with MS.4,30 The DSS was revised in
1983 to encompass more resolution with half
steps rather than unitary increments and has
become a universally accepted standard for measuring disability in MS.31
The result was the expanded disability status
scale (EDSS), which has since become the most
widely used outcome measure in MS trials.32 The
EDSS has been used to characterize trial populations and measure objective neurologic changes
in disease course. It carries the advantage of unifying clinical measurements in large multicenter
trials and allowing for cross-study comparisons.
MS clinicians are universally familiar with the
scale and its widespread acceptance by regulators
has favored its continued use in trials.33,34 Despite
the popularity of the EDSS, it is not without flaws
as the scale has been heavily criticized for high
inter-rater variability, especially in the earlier
steps, its disproportionate emphasis on walking,
exclusion of cognitive impairment, and the scale’s
inherent nonlinearity.
As DMTs became available in the decades following conception of the EDSS, trials required
increased sample sizes to detect differences in
treatment efficacy. In 1994, a task force was
formed to develop improved outcome measurements and address the shortcomings of the
EDSS,35 which resulted in the publication of the
4

MS functional composite (MSFC) in 1999.36 In
contrast to the neurologic examination focus of
the EDSS, the MSFC was created to measure the
major dimensions in which MS presents. It was
designed as a clinical trial outcome measure and
originally designed to capture four domains (i.e.
ambulation, arm function, cognitive function,
and vision); vision was excluded due to lack of
data on which to base inclusion. The MSFC was
required to correlate with the EDSS and assesses
function in three domains including gait, upper
extremity coordination, and cognition. The performance in each component is summarized
using a Z-score that represents the number of
standard deviations from a reference population.
The Z-scores are then averaged into a single composite score providing an outcome measure on a
continuous scale. The MSFC can be assessed
quickly and reliably and yields more sensitive
results than the EDSS and possesses predictive
validity. It has also been shown to correlate better
with MRI lesion burden and brain atrophy.37,38
Despite these advantages, the MSFC scale could
not replace the EDSS as the established gold
standard of measuring disability from MS. There
are problems with the MSFC, some of which can
be remedied, but the intuitive meaning of a composite Z-score is not easily translated into a clinically meaningful quantity. This caused the FDA
to have concerns around the original use of the
MSFC in the IMPACT trial,39 which had major
negative impacts on its adoption even though it
has been used in many trials since then.
The increased efficacy of DMTs have redefined
the goals of therapy, and disease activity-free status has become an attainable treatment goal.40,41
As more patients remain disease free with currently available DMTs, the concept of ‘no evidence of disease activity’ (NEDA) was proposed
and adopted in 2013, drawing from the term
NED used in oncology that refers to complete
cancer remission without ruling out recurrence.42
NEDA traditionally comprises assessment of
relapse rate, new or enlarged T2 or gadoliniumenhancing MRI lesions, and confirmed disability
worsening. Clinicians have recognized the merit
in the assessment of overall response to therapy
that is not adequately captured by these individual outcome measures. The concept of NEDA as
an outcome measure in MS trials has begun to see
use, and the definition of NEDA continues to
evolve as new components such as brain atrophy
and CSF neurofilament levels are incorporated.43
journals.sagepub.com/home/tan
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Currently, NEDA has not been validated in prospective studies to reflect long-term disease remission in patients at the individual level, and its
wider use is limited by the inability of the composite measure to capture specific mechanisms of
disease. The future of NEDA will likely adopt
new imaging and fluid biomarkers into treatment
monitoring, and additional experience with its
use will result in a more refined and uniform definition of the concept.
Collaborations in MS trials
The achievements in MS trials are founded on
collaboration among investigators, patients, pharmaceutical companies, and regulators. MS societies across different countries have provided
significant support with grants and activities that
fostered collaboration and advanced progress in
clinical trials. Multinational organizations such as
the European Committee for Treatment and
Research in MS and its US counterpart the
Americas Committee for Treatment and Research
in MS have played influential roles in the promotion and support of MS clinical trials. These
organizations were formed during an international meeting at Grand Island, NY, USA in
1982.44 The meeting also led to the formation of
the Advisory Committee on Clinical Trials of
New Agents in Multiple Sclerosis of the National
MS Society, which assisted in the design of future
trials in the upcoming decades. The meeting represented active efforts to foster clinical trials and
served as an important initial step forward for MS
research and future collaborations and
organizations.
Advances in information technologies have fostered the development of clinical trials and patient
databases. Collaborative efforts to create databases for epidemiologic studies and clinical trials
have been underway since the early part of the
20th century. The North American Registry
Committee on MS in Multiple Sclerosis was created in 1996 to collect longitudinal data on
patients with MS and assist with trial enrollment.
Clinical trial databases such as the large-scale
database from the Sylvia Lawry Center for MS
research provides information on over 20,000
patients with MS. The Multiple Sclerosis
Outcome Assessments Consortium placebo database provides information on placebo arms of
clinical trials.45 MSBase is the first online global
MS registry created in 2004 and now contains
journals.sagepub.com/home/tan

information on over 55,000 patients with MS.46 It
has provided important epidemiologic information and observational data on a large worldwide
population with MS.
Conclusion
Clinical trials in MS advanced from developments that objectively defined and quantified the
progression of a seemingly erratic disease and
keen observation that a pathway focused on
inflammation would lead to benefits if reduced or
controlled. The introduction and refinement of
MRI have led to visually quantifiable lesion loads
that can be used to track radiologic evidence of
disease burden and confirm periods of exacerbations. The evolving diagnostic criteria have
increased diagnostic sensitivity and simplified
enrollment in trials. Clinical outcome measures
such as the EDSS and MSFC allow objective
monitoring of disease progression. Together these
milestones paved the way for significant growth in
the landscape of MS trials but also created new
challenges for future trials. The rapid development of DMTs in MS has led to the decreased
feasibility of placebo trials due to ethical considerations and increased difficulty in detecting therapeutic effects compared with existing therapies.
Fewer resources from competition among trials
are demanding more efficient designs involving
shorter studies and fewer patients, but these
advances are limited by lack of biomarkers or surrogate outcomes. While much has been gained
from clinical trials in the ongoing investigation to
find the cause and cure of MS, the future of MS
trials holds potentials and challenges for the setting of new milestones that must be addressed.
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